Link To Us Link To Us

Bookmark Us Bookmark Us

Supplier Login Supplier Login

Linscott's Directory of Immunological & Biological Reagents
CAYMAN CHEMICAL COMPANY
 (http://www.caymanchem.com)

CAYMAN CHEMICAL COMPANY

1180 East Ellsworth Road

Ann Arbor MI 48108

Phone: (734) 971-3335

Phone: (800) 364-9897 (USA & Canada only)

Fax: (734) 971-3640

Customer Service: custserv@caymanchem.com
Technical Support: techserv@caymanchem.com
Sales: sales@caymanchem.com

Website: http://www.caymanchem.com

 
 
CAYMAN CHEMICAL COMPANY Products - Page 194 of 805
Page 194 of 805
Records 4,826 - 4,850 of 20,112
Name Description Size Catalog #
8(Z),14(Z)-Eicosadienoic Acid 8(Z),14(Z)-Eicosadienoic acid is an ω-8 C20:2 fatty acid. The presence of 8(Z),14(Z)-icosadienoic acid has been detected in human milk at a level of 0.19% (weight % total fatty acids).{16837} Eicosadienoic acids are converted by desaturases, in vivo, to eicosatrienoic acids, which are potent vasodilators. The physiological effects of 8(Z),14(Z)-eicosadienoic acid are unstudied. 100 µg 16854-100
8(Z),14(Z)-Eicosadienoic Acid 8(Z),14(Z)-Eicosadienoic acid is an ω-8 C20:2 fatty acid. The presence of 8(Z),14(Z)-icosadienoic acid has been detected in human milk at a level of 0.19% (weight % total fatty acids).{16837} Eicosadienoic acids are converted by desaturases, in vivo, to eicosatrienoic acids, which are potent vasodilators. The physiological effects of 8(Z),14(Z)-eicosadienoic acid are unstudied. 500 µg 16854-500
8,11,14-Eicosatriynoic Acid 8,11,14-Eicosatriynoic acid is an inhibitor of prostaglandin and leukotriene biosynthesis as well as arachidonic acid induced platelet aggregation.{14705} It inhibits cyclooxygenase (IC50 = 14 µM), human 12-lipoxygenase (IC50 = 0.46 µM), 5-lipoxygenase (IC50 = 25 µM) and the actions of slow-reacting substance of anaphylaxis (SRS-A) (IC50 = 10 µM).{14704,14706} 1 mg 10007900-1
8,11,14-Eicosatriynoic Acid 8,11,14-Eicosatriynoic acid is an inhibitor of prostaglandin and leukotriene biosynthesis as well as arachidonic acid induced platelet aggregation.{14705} It inhibits cyclooxygenase (IC50 = 14 µM), human 12-lipoxygenase (IC50 = 0.46 µM), 5-lipoxygenase (IC50 = 25 µM) and the actions of slow-reacting substance of anaphylaxis (SRS-A) (IC50 = 10 µM).{14704,14706} 10 mg 10007900-10
8,11,14-Eicosatriynoic Acid 8,11,14-Eicosatriynoic acid is an inhibitor of prostaglandin and leukotriene biosynthesis as well as arachidonic acid induced platelet aggregation.{14705} It inhibits cyclooxygenase (IC50 = 14 µM), human 12-lipoxygenase (IC50 = 0.46 µM), 5-lipoxygenase (IC50 = 25 µM) and the actions of slow-reacting substance of anaphylaxis (SRS-A) (IC50 = 10 µM).{14704,14706} 5 mg 10007900-5
8,12-iso-iPF2α-VI-1,5-lactone A racemic mixture of the lactone form of the free acid, 8,12-iso- iPF2α-VI; the free acid is the most abundant F2-iP2 regioisomer measured in the urine of rats treated to induce lipid peroxidation; used as a biomarker for oxidative stress 100 µg 10312-100
8,12-iso-iPF2α-VI-1,5-lactone A racemic mixture of the lactone form of the free acid, 8,12-iso- iPF2α-VI; the free acid is the most abundant F2-iP2 regioisomer measured in the urine of rats treated to induce lipid peroxidation; used as a biomarker for oxidative stress 25 µg 10312-25
8,12-iso-iPF2α-VI-1,5-lactone A racemic mixture of the lactone form of the free acid, 8,12-iso- iPF2α-VI; the free acid is the most abundant F2-iP2 regioisomer measured in the urine of rats treated to induce lipid peroxidation; used as a biomarker for oxidative stress 50 µg 10312-50
8,12-iso-iPF2α-VI-d11 An internal standard for the quantification of 8,12-iso-iPF2α-VI by GC- or LC-MS. 10 µg 10006878-10
8,12-iso-iPF2α-VI-d11 An internal standard for the quantification of 8,12-iso-iPF2α-VI by GC- or LC-MS. 25 µg 10006878-25
8,12-iso-iPF2α-VI-d11 An internal standard for the quantification of 8,12-iso-iPF2α-VI by GC- or LC-MS. 50 µg 10006878-50
8,9-EE-14(Z)-E A minor product from the synthesis of 14,15-EE-8(Z)-E 100 µg 18112-100
8,9-EE-14(Z)-E A minor product from the synthesis of 14,15-EE-8(Z)-E 25 µg 18112-25
8,9-EE-14(Z)-E A minor product from the synthesis of 14,15-EE-8(Z)-E 50 µg 18112-50
8,9-EE-14(Z)-E A minor product from the synthesis of 14,15-EE-8(Z)-E 500 µg 18112-500
8-bromo-cGMP (sodium salt) A cell-permeable analog of cGMP that preferentially activates cGMP-dependent protein kinase; 1 µM-0.1 mM inhibits acetylcholine-induced increases in intracellular calcium concentrations 10 mg 15992-10
8-bromo-cGMP (sodium salt) A cell-permeable analog of cGMP that preferentially activates cGMP-dependent protein kinase; 1 µM-0.1 mM inhibits acetylcholine-induced increases in intracellular calcium concentrations 25 mg 15992-25
8-bromo-cGMP (sodium salt) A cell-permeable analog of cGMP that preferentially activates cGMP-dependent protein kinase; 1 µM-0.1 mM inhibits acetylcholine-induced increases in intracellular calcium concentrations 5 mg 15992-5
8-bromo-cGMP (sodium salt) A cell-permeable analog of cGMP that preferentially activates cGMP-dependent protein kinase; 1 µM-0.1 mM inhibits acetylcholine-induced increases in intracellular calcium concentrations 50 mg 15992-50
8-bromo-Cyclic AMP (sodium salt) A cell permeable analog of cAMP that activates PKA with a Ka value of 0.05 µM; more stable to hydrolysis and has increased membrane permeability compared to unmodified cAMP 10 mg 14431-10
8-bromo-Cyclic AMP (sodium salt) A cell permeable analog of cAMP that activates PKA with a Ka value of 0.05 µM; more stable to hydrolysis and has increased membrane permeability compared to unmodified cAMP 25 mg 14431-25
8-bromo-Cyclic AMP (sodium salt) A cell permeable analog of cAMP that activates PKA with a Ka value of 0.05 µM; more stable to hydrolysis and has increased membrane permeability compared to unmodified cAMP 5 mg 14431-5
8-Bromoisoquinoline 8-Bromoisoquinoline is a synthetic intermediate useful for pharmaceutical synthesis. 1 g 10007082-1
8-Bromoisoquinoline 8-Bromoisoquinoline is a synthetic intermediate useful for pharmaceutical synthesis. 5 g 10007082-5
8-Bromoisoquinoline 8-Bromoisoquinoline is a synthetic intermediate useful for pharmaceutical synthesis. 500 mg 10007082-500
© 1980 - 2015 Linscott's Directory, Linscott's USA. All rights reserved.